Get access

The current clinical management of Huntington's disease

Authors

  • Wendy Phillips MD,

    1. Cambridge Centre for Brain Repair, E.D. Adrian Building, Forvie Site, Cambridge, United Kingdom
    2. Department of Neurology, Addenbrooke's Hospital, Hills Road, Cambridge, United Kingdom
    Search for more papers by this author
  • Kathleen M. Shannon MD,

    1. Rush University Medical Center, Chicago, Illinois, USA
    Search for more papers by this author
  • Roger A. Barker MD

    Corresponding author
    1. Cambridge Centre for Brain Repair, E.D. Adrian Building, Forvie Site, Cambridge, United Kingdom
    2. Department of Neurology, Addenbrooke's Hospital, Hills Road, Cambridge, United Kingdom
    • Cambridge Centre for Brain Repair, E.D. Adrian Building, Forvie Site, Cambridge, CB2 2PY, United Kingdom
    Search for more papers by this author

Abstract

Huntington's disease is a neurodegenerative condition, characterized by movement disorders, cognitive decline, and psychiatric disturbance. We review the pharmacological management of the various movement disorders associated with the disease, the cognitive decline and the commonly encountered behavioral disturbances. We discuss the nonclassical features of the disease, important in the management of these patients. Nonpharmacological support including genetic counseling and therapy and the importance of palliative care are also addressed. Finally, experimental approaches that may soon impact upon clinical practice are discussed. © 2008 Movement Disorder Society

Ancillary